Guiding Management to Market

DCi Biotech guides global pharmaceutical, medical device and biotech companies through the complicated processes required to bring cell therapies to market. Our business advice addresses cell therapy commercialization issues, such as meeting Regulatory requirements, obtaining reimbursement, minimizing cost of goods, and optimizing clinical trial design.

Our distinctive expertise allows us to evaluate and advise on organic opportunities, as well as perform due diligence on external investments, including placements, licensing, and acquisitions. We also work with management teams to develop business plans and presentations for investors.

DCi Biotech is a unique consulting practice. It combines extensive biotech and pharmaceutical industry experience with an understanding of the science and medicine behind cell-based therapeutics—a major asset for decision makers seeking business advice in regenerative medicine.
» Read More

News

June 15, 2013
Australian Cell Therapy in 2013 » More

March 03, 2012
Cell Therapy Reimbursement » More

February 21, 2012
Asia Pacific Success Stories » More

January 31, 2012
Stem Cell Research & Regen Medicine Conference » More

June 01, 2011
Australia- Biotech Gateway » More

» News archive